Alan Gary Epstein

Address:

11625 Montana Ave APT 130, Los Angeles, CA 90049

Phone:

(310)4711002

VIN:

WDBWK54FX9F190298

Make:

MERCEDES-BENZ

Model:

SLK-CLASS

Year:

2009

US Patent:

6403096, Jun 11, 2002

Filed:

Nov 18, 1999

Appl. No.:

09/443061

Inventors:

Alan L. Epstein - La Canada CA
Leslie A. Khawli - Arcadia CA

Assignee:

University of Southern California - Los Angeles CA

International Classification:

A61K 3820

US Classification:

42419511, 530324, 530351, 530402, 514 2, 514 8, 514 12, 4241921, 424 852

Abstract:

A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.

US Patent:

6524823, Feb 25, 2003

Filed:

Jul 27, 2001

Appl. No.:

09/916883

Inventors:

Alan L. Epstein - La Canada CA
Michael Glovsky - Los Angeles CA

Assignee:

The University of Southern California - Los Angeles CA

International Classification:

C12P 2104

US Classification:

435 696, 435 7021, 4241781, 4241551, 4241761, 4241801, 4241831, 530350, 530380, 530382, 5303871, 5303881, 5303911

Abstract:

Liposomal conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.

US Patent:

6696276, Feb 24, 2004

Filed:

Jan 13, 2003

Appl. No.:

10/342426

Inventors:

Alan L. Epstein - La Canada CA
Michael Glovsky - Los Angeles CA

Assignee:

University of Southern California - Los Angeles CA

International Classification:

C12P 2104

US Classification:

435 696, 4241781, 530382

Abstract:

Liposomal conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.

US Patent:

6737064, May 18, 2004

Filed:

May 9, 2002

Appl. No.:

10/142120

Inventors:

Alan L. Epstein - La Canada CA
Leslie A. Khawli - Arcadia CA

Assignee:

The University of Southern California - Los Angeles CA

International Classification:

A61K 3820

US Classification:

42419511, 514 2, 514 8, 514 12, 4241931, 424 91

Abstract:

A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.

US Patent:

6871487, Mar 29, 2005

Filed:

Feb 14, 2003

Appl. No.:

10/367227

Inventors:

Anthony D. Kurtz - Ridgewood NJ, US
John Chivers - Derby, GB
Alan Epstein - Lexington MA, US

Assignee:

Kulite Semiconductor Products, Inc. - Leonia NJ

International Classification:

F02C009/54

US Classification:

60 39281, 60 3927, 60795

Abstract:

The present invention relates to a system for detecting aerodynamic instabilities in a jet turbine engine having a pressure transducer mounted in the engine. The pressure transducer, welded to a circuit in signal communication with a controller, is adapted to send measured pressure readings from air in a combustion chamber to the controller. The controller, located in spaced apart relation from the engine, is adapted by software to detect pressure patterns from the pressure signals generated by the transducer that are indicative of a stall or surge. A series of fuel and air valves located with compression and combustion chambers of the engine are in signal communication with the controller. The controller in response to detecting pressure signals indicating a stall or surge is operative to signals in the valves to change the air flow, air angle, fuel flow or speed to reduce the possibility of a stall or surge.

US Patent:

7159401, Jan 9, 2007

Filed:

Dec 23, 2004

Appl. No.:

11/023035

Inventors:

Anthony D. Kurtz - Ridgewood NJ, US
John Chivers - Derby, GB
Alan Epstein - Lexington MA, US

Assignee:

Kulite Semiconductor Products, Inc. - Leonia NJ

International Classification:

F02C 9/54

US Classification:

60772

Abstract:

The present invention relates to a system for detecting aerodynamic instabilities in a jet turbine engine having a pressure transducer mounted in the engine. The pressure transducer, welded to a circuit in signal communication with a controller, is adapted to send measured pressure readings from air in a combustion chamber to the controller. The controller, located in spaced apart relation from the engine, is adapted by software to detect pressure patterns from the pressure signals generated by the transducer that are indicative of a stall or surge. A series of fuel and air valves located with compression and combustion chambers of the engine are in signal communication with the controller. The controller in response to detecting pressure signals indicating a stall or surge is operative to signals in the valves to change the air flow, air angle, fuel flow or speed to reduce the possibility of a stall or surge.

US Patent:

7371371, May 13, 2008

Filed:

Aug 12, 2002

Appl. No.:

10/218197

Inventors:

Alan L. Epstein - La Canada CA, US
Peisheng Hu - Covina CA, US

Assignee:

University of Southern California - Los Angeles CA

International Classification:

A61K 38/20
C07K 14/55

US Classification:

424 852, 530351

Abstract:

Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildtype form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.

US Patent:

7514073, Apr 7, 2009

Filed:

Mar 29, 2005

Appl. No.:

11/093073

Inventors:

Alan L. Epstein - La Canada CA, US
Peisheng Hu - Covina CA, US

Assignee:

University of Southern California - Los Angeles CA

International Classification:

A61K 38/20

US Classification:

424 852, 514885

Abstract:

Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildytpe form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.